[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 27 of about 27
1. Wong M, Grossman J, Hahn BH, La Cava A: Cutaneous vasculitis in breast cancer treated with chemotherapy. Clin Immunol; 2008 Oct;129(1):3-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous vasculitis in breast cancer treated with chemotherapy.
  • A patient from the University of California Los Angeles Medical Center who developed cutaneous vasculitis during the course of treatment for metastatic breast cancer is presented (status: post-lumpectomy and radiation therapy).
  • Since the onset of vasculitis occurred during the course of therapy for the neoplasm, it was difficult to differentiate between drug-induced vasculitis and paraneoplastic vasculitis.
  • The patient had been exposed to medications including gabapentin, methimazole, trastuzumab, fulvestrant, and letrozole - which could cause endothelial cell toxicity.
  • Drug-induced small vessel vasculitis usually attacks the skin or subcutaneous parts of the skin.
  • In cancer therapy, there have been case reports that hormonal drugs such as estrogen receptor antagonists, aromatase inhibitors, and epidermal growth factor receptor (EGFR) inhibitors can induce cutaneous vasculitis.
  • On the other hand, paraneoplastic syndromes manifested as cutaneous vasculitis have been documented, possibly mediated by unknown immunological mechanisms associated with the tumor such as formation of immune complexes, direct antibody-mediated effects on endothelial cells, or direct effects of tumor cells on the vascular wall.
  • Some patients with drug-induced cutaneous vasculitis have antineutrophil cytoplasm antibodies (ANCA) directed to one or more neutrophil cytoplasm antigens - the most common being granule protein myeloperoxidase (MPO), human leukocyte elastase (HLE), cathepsin G and lactoferrin.
  • Serologic testing and measurements suggest an influence of therapy on vasculitis, yet the lack of sensitivity and specificity for a biomarker in endothelial injury indicate the need to search and evaluate new markers for improved predictive value of the tests, and to provide guidance in therapy.

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Vasculitis.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Vasculitis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. ANASTROZOLE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1989 May 12;244(4905):707-12 [2470152.001]
  • [Cites] Endocr Relat Cancer. 2004 Sep;11(3):391-406 [15369444.001]
  • [Cites] J Rheumatol. 1990 Nov;17(11):1458-62 [2273485.001]
  • [Cites] EMBO J. 1992 Mar;11(3):961-71 [1312467.001]
  • [Cites] Clin Dermatol. 1993 Jan-Mar;11(1):175-87 [8339194.001]
  • [Cites] Arch Intern Med. 1994 Feb 14;154(3):334-40 [8297201.001]
  • [Cites] J Cutan Pathol. 1993 Oct;20(5):407-10 [8300925.001]
  • [Cites] Curr Opin Rheumatol. 1996 Jan;8(1):30-3 [8867536.001]
  • [Cites] Clin Nephrol. 1997 May;47(5):336-40 [9181282.001]
  • [Cites] Semin Oncol. 1997 Jun;24(3):334-59 [9208889.001]
  • [Cites] Rev Rhum Engl Ed. 1997 Dec;64(12):816-24 [9476271.001]
  • [Cites] Genes Dev. 2004 Nov 15;18(22):2699-711 [15545627.001]
  • [Cites] Ann Rheum Dis. 2005 Apr;64(4):651-2 [15769928.001]
  • [Cites] J Dtsch Dermatol Ges. 2005 Aug;3(8):599-606 [16033478.001]
  • [Cites] Clin Adv Hematol Oncol. 2003 Apr;1(4):218-9 [16224409.001]
  • [Cites] Am J Dermatopathol. 2005 Dec;27(6):504-28 [16314707.001]
  • [Cites] Cell Cycle. 2006 Aug;5(15):1654-61 [16861913.001]
  • [Cites] Oncogene. 2006 Nov 2;25(52):6986-96 [16715132.001]
  • [Cites] Ann Oncol. 2007 Jan;18(1):205-7 [17043095.001]
  • [Cites] World J Surg Oncol. 2007;5:9 [17244373.001]
  • [Cites] Acta Reumatol Port. 2007 Apr-Jun;32(2):181-3 [17572653.001]
  • [Cites] Ann Oncol. 2007 Sep;18(9):1582-3 [17761714.001]
  • [Cites] Curr Opin Rheumatol. 2008 Jan;20(1):35-9 [18281855.001]
  • [Cites] N Engl J Med. 2008 Mar 13;358(11):1160-74 [18337605.001]
  • [Cites] Arthritis Rheum. 2000 Feb;43(2):405-13 [10693882.001]
  • [Cites] Clin Exp Rheumatol. 2000 May-Jun;18(3):305-7 [10895365.001]
  • [Cites] Baillieres Best Pract Res Clin Rheumatol. 2000 Sep;14(3):515-33 [10985984.001]
  • [Cites] Genes Dev. 2000 Sep 15;14(18):2283-97 [10995386.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Nov;85(11):4270-3 [11095466.001]
  • [Cites] Br J Dermatol. 2001 Jun;144(6):1169-76 [11422037.001]
  • [Cites] Ann Oncol. 2001;12 Suppl 1:S23-8 [11521717.001]
  • [Cites] Eur J Cancer. 2001 Sep;37 Suppl 4:S3-8 [11597398.001]
  • [Cites] Am J Med. 1986 Jun;80(6):1027-30 [3728500.001]
  • [Cites] Arch Dermatol. 1986 Jul;122(7):765-7 [3729508.001]
  • [Cites] Medicine (Baltimore). 1988 Jul;67(4):220-30 [3292873.001]
  • [Cites] J Cell Sci. 2001 Aug;114(Pt 15):2711-2 [11683405.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):110-24 [11773160.001]
  • [Cites] Ann Pharmacother. 2002 Jan;36(1):130-47 [11816242.001]
  • [Cites] Scand J Rheumatol. 2002;31(1):46-9 [11924649.001]
  • [Cites] Br J Dermatol. 2002 Sep;147(3):598-601 [12207609.001]
  • [Cites] Acta Derm Venereol. 2002;82(3):206-8 [12353714.001]
  • [Cites] J Am Acad Dermatol. 2003 Apr;48(4):497-507 [12664010.001]
  • [Cites] Arthritis Care Res. 2000 Dec;13(6):417-23 [14635319.001]
  • [Cites] Leuk Lymphoma. 2004 Apr;45(4):811-3 [15160961.001]
  • [Cites] Ann Oncol. 2004 Jul;15(7):1007-12 [15205192.001]
  • [Cites] Ann Intern Med. 1990 Jun 15;112(12):965-6 [2140253.001]
  • (PMID = 18640073.001).
  • [ISSN] 1521-7035
  • [Journal-full-title] Clinical immunology (Orlando, Fla.)
  • [ISO-abbreviation] Clin. Immunol.
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / R01 AR053239; United States / NIAMS NIH HHS / AR / R01 AR053239-03; United States / NIAID NIH HHS / AI / R37 AI046776; United States / NIAID NIH HHS / AI / AI046776-09; United States / NIAMS NIH HHS / AR / AR53463; United States / NIAID NIH HHS / AI / AI 46776; United States / NIAID NIH HHS / AI / R37 AI046776-09; United States / NIAMS NIH HHS / AR / T32 AR053463; United States / NIAMS NIH HHS / AR / T32 AR053463-02; United States / NIAMS NIH HHS / AR / AR53239; United States / NIAMS NIH HHS / AR / AR053463-02; United States / NIAMS NIH HHS / AR / AR053239-03
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Nitriles; 0 / Triazoles; 094ZI81Y45 / Tamoxifen; 2Z07MYW1AZ / anastrozole; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ NIHMS71593; NLM/ PMC2579274
  •  go-up   go-down


2. Hamidou MA, El Kouri D, Audrain M, Grolleau JY: Systemic antineutrophil cytoplasmic antibody vasculitis associated with lymphoid neoplasia. Ann Rheum Dis; 2001 Mar;60(3):293-5
MedlinePlus Health Information. consumer health - Vasculitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic antineutrophil cytoplasmic antibody vasculitis associated with lymphoid neoplasia.
  • Two cases of systemic antineutrophil cytoplasmic antibody (ANCA) vasculitis in the setting of chronic lymphocytic leukaemia and angioimmunoblastic lymphadenopathy type T cell lymphoma are reported.
  • The two patients had fever of unknown origin associated with cutaneous vasculitis and "pulmonary-renal syndrome" with alveolar haemorrhage.
  • Despite anti-infectious treatments, steroids, and chemotherapy, the vasculitis had a fatal paraneoplastic course in several weeks.
  • When infection is excluded in patients with malignancy, atypical features should be promptly investigated for systemic vasculitis, and an ANCA test performed.
  • [MeSH-major] Antibodies, Antineutrophil Cytoplasmic / immunology. Leukemia, Lymphocytic, Chronic, B-Cell / complications. Lymphoma, T-Cell / complications. Vasculitis / etiology

  • Genetic Alliance. consumer health - Vasculitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11171697.001).
  • [ISSN] 0003-4967
  • [Journal-full-title] Annals of the rheumatic diseases
  • [ISO-abbreviation] Ann. Rheum. Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Antineutrophil Cytoplasmic
  • [Other-IDs] NLM/ PMC1753562
  •  go-up   go-down


3. Demidov LV, Semenkova EN, Kharkevich GIu, Timofeev IV: [Use of interleukine-2 in a patient with renal cancer and paraneoplastic vasculitis]. Ter Arkh; 2004;76(10):23-5
MedlinePlus Health Information. consumer health - Vasculitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Use of interleukine-2 in a patient with renal cancer and paraneoplastic vasculitis].
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Interleukin-2 / administration & dosage. Kidney Neoplasms / drug therapy. Paraneoplastic Syndromes / drug therapy. Vasculitis / drug therapy

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Vasculitis.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15575472.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Russia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interleukin-2
  •  go-up   go-down


Advertisement
4. Sbidian E, Pruvost C, Zagdanski AM, Dubertret L, Flageul B: [Pneumatosis cystoides intestinalis complicating paraneoplastic dermatomyositis]. Ann Dermatol Venereol; 2008 Oct;135(10):668-71
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pneumatosis cystoides intestinalis complicating paraneoplastic dermatomyositis].
  • We report a new case of PCI occurring during the course of paraneoplastic dermatomyositis.
  • Relapse of dermatomyositis preceded the discovery of metastases for which chemotherapy was initiated with 5-fluorouracil and vinorelbine.
  • Abdominal computed tomography scan showed gas collection in the mesentery, revealing the PCI.
  • The patient slowly improved with symptomatic treatment.
  • In collagen diseases, several hypotheses have been suggested: digestive hypokinesia, corticosteroid-induced ulceration and intestinal vasculitis.
  • Diagnosis of PCI is based on abdominal computed tomography.
  • Although rare, the diagnosis of PCI must be evoked in collagen disorder patients presenting nonspecific abdominal symptoms.
  • [MeSH-major] Dermatomyositis / complications. Paraneoplastic Syndromes / complications. Pneumatosis Cystoides Intestinalis / complications

  • Genetic Alliance. consumer health - Dermatomyositis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18929916.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


5. Martin AC, Friedlander M, Kiernan MC: Paraneoplastic mononeuritis multiplex in non-small-cell lung carcinoma. J Clin Neurosci; 2006 Jun;13(5):595-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paraneoplastic mononeuritis multiplex in non-small-cell lung carcinoma.
  • A 60-year-old man developed two selective peripheral mononeuropathies of the peroneal and later the radial nerve, shortly after a diagnosis of large-cell lung carcinoma.
  • Subsequent magnetic resonance imaging of the lower limb excluded focal compression or malignant infiltration along the course of the peroneal nerve, and there was no signal change within the nerve, prompting a diagnosis of paraneoplastic mononeuritis multiplex.
  • Anti-neuronal antibodies and serological markers of systemic vasculitis were negative.
  • Neither the patient's large-cell lung carcinoma nor mononeuritis multiplex responded to chemotherapy, and he died within 6 months of the initial diagnosis.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / radiography. Paraneoplastic Polyneuropathy / radiography. Peroneal Neuropathies / radiography. Radial Neuropathy / radiography

  • Genetic Alliance. consumer health - Mononeuritis multiplex.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16564174.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


6. Nozato K, Morishima Y, Furuta J, Fujita J, Miyazaki K, Ogawa R, Kikuchi N, Sakamoto T, Hizawa N: [A case of Henoch-Schönlein purpura which was difficult to distinguish from a skin rash associated with gefitinib]. Nihon Kokyuki Gakkai Zasshi; 2010 Jul;48(7):529-34
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A skin biopsy revealed leukocytoclastic vasculitis in the superficial dermis and immunofluorescence also showed the presence of C3 depositions within the blood vessel walls, which led to a diagnosis of Henoch-Schönlein purpura.
  • The purpura gradually improved with topical steroids and bed rest; however, gefitinib had to be discontinued because of a growing papulopustular rash with intense itching, and as a result of the discontinuation, both types of skin lesions resolved.
  • Two months later, she resumed gefitinib treatment since her level of CEA began to rise.
  • Even though the papulopustular rash developed after the readministration of gefitinib, there had been no evidence of Henoch-Schönlein purpura recurrence during 2.5 years follow-up.
  • This case, however, suggests that not only drug eruption but also paraneoplastic vasculitis should be considered in the differential diagnosis of palpable purpura in patients with non-small cell lung cancer receiving treatment with gefitinib.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Exanthema / chemically induced. Exanthema / diagnosis. Paraneoplastic Syndromes / diagnosis. Purpura, Schoenlein-Henoch / diagnosis. Quinazolines / adverse effects
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Lung Neoplasms / drug therapy. Middle Aged. Small Cell Lung Carcinoma / drug therapy

  • Genetic Alliance. consumer health - Henoch-Schonlein purpura.
  • MedlinePlus Health Information. consumer health - Rashes.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20684219.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


7. Paydaş S, Zorludemir S, Sahin B: Vasculitis and leukemia. Leuk Lymphoma; 2000 Dec;40(1-2):105-12
MedlinePlus Health Information. consumer health - Vasculitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vasculitis and leukemia.
  • Vasculitis may accompany neoplasias and be of paraneoplastic type or associated with drugs used in patient treatment.
  • We evaluated skin biopsies of twenty-eight cases with vasculitis accompanying leukemias reviewed and clinical outcome was evaluated.
  • Eleven of the 28 cases had paraneoplastic vasculitis and 17 had vasculitis associated with various drugs including chemotherapy, cytokines and antibacterial agents.
  • Paraneoplastic vasculitis was seen in 3 cases with chronic myelocytic leukemia in blastic phase, 5 patients with acute myeloblastic leukemia, and 3 with myelodysplastic syndrome.
  • Drugs responsible for the 17 cases of vasculitis included hydroxyurea, vincristine, cytosine-arabinoside, methotrexate, all-trans retinoic acid, granulocyte-colony stimulating factor, interferon and antibiotics.
  • Paraneoplastic vasculitis is not rare in leukemias and may be a manifestation of the blastic phase of chronic myeloid leukemia.
  • Furthermore paraneoplastic vasculitis can be fatal in myelodysplastic syndromes and may be present clinically before the specific diagnosis is made.
  • Drugs used in routine therapy may be the cause of the vasculitis, thus skin biopsy should be performed in all cutaneous lesions in patients with hemopoietic neoplasias.
  • [MeSH-major] Leukemia / complications. Vasculitis / etiology

  • Genetic Alliance. consumer health - Vasculitis.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11426610.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 0 / Antineoplastic Agents
  •  go-up   go-down


8. Vandergheynst F, Van Gansbeke D, Cogan E: Wegener's granulomatosis masquerading as a renal cancer: a case report and review of the literature. Clin Exp Rheumatol; 2006 Sep-Oct;24(5):584-6
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As abdominal tomodensitometry detected a tumoral process of the left kidney, a paraneoplastic vasculitis associated with a renal cancer was suspected.
  • [MeSH-minor] Adult. Antibodies, Antineutrophil Cytoplasmic / blood. Biopsy. Cyclophosphamide / therapeutic use. Diagnosis, Differential. Drug Therapy, Combination. Granuloma, Plasma Cell / diagnosis. Humans. Immunosuppressive Agents / therapeutic use. Male. Methylprednisolone / therapeutic use


9. Cabuk M, Inanir I, Türkdoğan P, Ceylan C, Değirmenci M, Türel A, Ozdemir E: Cyclic lymphocytic vasculitis associated with chronic lymphocytic leukemia. Leuk Lymphoma; 2004 Apr;45(4):811-3
MedlinePlus Health Information. consumer health - Vasculitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclic lymphocytic vasculitis associated with chronic lymphocytic leukemia.
  • Lymphocytic cutaneous vasculitis associated with a haematological malignancy has rarely been reported.
  • These lesions improved after all combination chemotherapy courses and recurred before each course.
  • Repetitive skin biopsies revealed lymphocytic vasculitis.
  • After 7 courses of chemotherapy, she had a complete remission.
  • The cyclic pattern of lymphocytic vasculitis and its relation with CLL disease activity are interesting clinical features in this case.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / complications. Vasculitis / etiology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Middle Aged. Paraneoplastic Syndromes / etiology. Remission Induction. Skin Diseases, Vascular / etiology. T-Lymphocytes / pathology


10. Carlson JA, Cavaliere LF, Grant-Kels JM: Cutaneous vasculitis: diagnosis and management. Clin Dermatol; 2006 Sep-Oct;24(5):414-29
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous vasculitis: diagnosis and management.
  • Vasculitis is histologically defined as inflammatory cell infiltration and destruction of blood vessels.
  • Vasculitis is classified as primary (idiopathic, eg, cutaneous leukocytoclastic angiitis, Wegener's granulomatosis) or secondary, a manifestation of connective tissue diseases, infections, adverse drug eruptions, or a paraneoplastic phenomenon.
  • Cutaneous vasculitis, manifested as urticaria, purpura, hemorrhagic vesicles, ulcers, nodules, livedo, infarcts, or digital gangrene, is a frequent and often significant component of many systemic vasculitic syndromes such as lupus or rheumatoid vasculitis and antineutrophil cytoplasmic antibody-associated primary vasculitic syndromes such as Churg-Strauss syndrome.
  • In most instances, cutaneous vasculitis represents a self-limited, single-episode phenomenon, the treatment of which consists of general measures such as leg elevation, warming, avoidance of standing, cold temperatures and tight fitting clothing, and therapy with antihistamines, aspirin, or nonsteroidal anti-inflammatory drugs.
  • More extensive therapy is indicated for symptomatic, recurrent, extensive, and persistent skin disease or coexistence of systemic disease.
  • In cases of refractory vasculitis, plasmapheresis and intravenous immunoglobulin are viable considerations.
  • The new biologic therapies that work via cytokine blockade or lymphocyte depletion such as tumor alpha inhibitor infliximab and the anti-B-cell antibody rituximab, respectively, are showing benefit in certain settings such as Wegener's granulomatosis, antineutrophil cytoplasmic antibody-associated vasculitis, Behçet's disease, and cryoglobulinemic vasculitis.
  • [MeSH-major] Skin Diseases / diagnosis. Skin Diseases / therapy. Vasculitis / diagnosis. Vasculitis / therapy
  • [MeSH-minor] Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Antibodies, Antineutrophil Cytoplasmic / metabolism. Histamine H1 Antagonists / therapeutic use. Humans. Immunosuppressive Agents / therapeutic use. Incidence. Skin / drug effects. Skin / immunology. Skin / pathology. Temperature

  • Genetic Alliance. consumer health - Vasculitis.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • MedlinePlus Health Information. consumer health - Vasculitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16966021.001).
  • [ISSN] 0738-081X
  • [Journal-full-title] Clinics in dermatology
  • [ISO-abbreviation] Clin. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antibodies, Antineutrophil Cytoplasmic; 0 / Histamine H1 Antagonists; 0 / Immunosuppressive Agents
  • [Number-of-references] 170
  •  go-up   go-down


11. Wang CC, Chen MJ, Ho HC, Hong HS: Urticarial vasculitis and dermatomyositis in a patient with nasopharyngeal carcinoma. Cutis; 2003 Nov;72(5):399-402
MedlinePlus Health Information. consumer health - Vasculitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urticarial vasculitis and dermatomyositis in a patient with nasopharyngeal carcinoma.
  • Urticarial vasculitis has rarely been described in association with polymyositis.
  • We report the case of a 37-year-old man with dermatomyositis and nasopharyngeal carcinoma who presented initially with urticarial vasculitis.
  • The lesions of urticarial vasculitis were initially photodistributed, indicating photosensitivity.
  • The patient was treated with systemic steroids, chemotherapy (cisplatin and fluorouracil), and radiation therapy.
  • The tumor and urticarial vasculitis completely resolved, and the myositis improved.
  • [MeSH-major] Dermatomyositis / diagnosis. Nasopharyngeal Neoplasms / diagnosis. Paraneoplastic Syndromes / diagnosis. Vasculitis / diagnosis
  • [MeSH-minor] Adult. Arm. Combined Modality Therapy. Diagnosis, Differential. Humans. Male. Neck


12. Jaing TH, Hsueh C, Chiu CH, Shih IH, Chan CK, Hung IJ: Cutaneous lymphocytic vasculitis as the presenting feature of acute lymphoblastic leukemia. J Pediatr Hematol Oncol; 2002 Oct;24(7):555-7
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous lymphocytic vasculitis as the presenting feature of acute lymphoblastic leukemia.
  • A skin biopsy demonstrated a T-cell-mediated lymphocytic vasculitis.
  • After the patient started chemotherapy, the skin lesions abated but she became febrile and a blood culture revealed cryptococci.
  • The relationship between lymphocytic vasculitis and acute lymphoblastic leukemia may be an example of paraneoplastic association because both conditions seem to have appeared at about the same time, and both followed a parallel course.
  • Lymphocytic vasculitis may also reflect a new manifestation of host-leukemia interaction.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Skin / pathology. Vasculitis / complications. Vasculitis / pathology
  • [MeSH-minor] Anti-Bacterial Agents / therapeutic use. Antineoplastic Agents / therapeutic use. Biopsy. Bone Marrow / pathology. Child. Humans. Prednisolone / therapeutic use


13. Hachulla E: [Systemic urticarias]. Ann Dermatol Venereol; 2003 May;130 Spec No 1:1S53-68
MedlinePlus Health Information. consumer health - Hives.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most of cases are urticarial vasculitis consequence of inflammatory injury of capillaries and postcapillary venules in the skin.
  • If hypocomplementemic urticarial vasculitis syndrome is a classical cause, the majority of patients have an underlying systemic disease like systemic lupus erythematosus, Sjögren's syndrome, mixed cryoglobulinemia, Still disease or cancer.
  • Others systemic urticaria have been reported without clearly evidence of vasculitis like in primary or acquired angioedema, hereditary periodic fever syndromes and in some thyroiditis.
  • Diagnosis needs a step to step procedure.
  • Treatment depends the underlying disease.
  • Some patients respond to nonsteroidal antiinflammatory drugs, some other need corticosteroids or immunosuppression.
  • If urticarial vasculitis seems isolated in the absence of chronic obstructive pulmonary disease, antihistamines, nonsteroidal antiinflammatory drugs, colchicine, dapsone or hydroxychloroquine must be first used.
  • [MeSH-minor] Angioedema / genetics. Autoimmune Diseases / complications. Chronic Disease. Cryoglobulinemia / complications. Familial Mediterranean Fever / complications. Humans. Immune Complex Diseases / complications. Neoplasms / complications. Paraneoplastic Syndromes / etiology. Vasculitis / complications. Vasculitis / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12843810.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 64
  •  go-up   go-down


14. Demopoulos A, DeAngelis LM: Neurologic complications of leukemia. Curr Opin Neurol; 2002 Dec;15(6):691-9
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE OF REVIEW: As treatment of the leukemias improves, patients are surviving longer.
  • Recognizing and rapidly treating metastatic complications or avoiding neurotoxic therapies improves outcome, reduces morbidity and mortality, and limits long-term sequelae.
  • RECENT FINDINGS: Neurologic dysfunction may result from leukemic infiltration of the nervous system or as a consequence of chemotherapy or prophylactic craniospinal irradiation.
  • The present review summarizes common problems in the neurologic complications of leukemia and discusses recent advancements in their diagnosis and treatment.
  • [MeSH-minor] Blood Viscosity. Disseminated Intravascular Coagulation / etiology. Humans. Leukemic Infiltration / complications. Leukostasis / etiology. Magnetic Resonance Imaging. Meningeal Neoplasms / pathology. Meningeal Neoplasms / secondary. Paraneoplastic Syndromes, Nervous System / etiology. Tomography, X-Ray Computed. Vasculitis / etiology. Venous Thrombosis / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Lippincott Williams & Wilkins
  • (PMID = 12447107.001).
  • [ISSN] 1350-7540
  • [Journal-full-title] Current opinion in neurology
  • [ISO-abbreviation] Curr. Opin. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 44
  •  go-up   go-down


15. Rosen CL, DePalma L, Morita A: Primary angiitis of the central nervous system as a first presentation in Hodgkin's disease: a case report and review of the literature. Neurosurgery; 2000 Jun;46(6):1504-8; discussion 1508-10
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Radiographic examination revealed a right temporal lobe area with edema, and mild contrast enhancement was noted on computed tomography and magnetic resonance imaging.
  • Dexamethasone as well as chemotherapy for Hodgkin's disease was initiated.
  • However, of six patients who presented with central nervous system angiitis and concurrent Hodgkin's disease and who underwent aggressive treatment for both conditions, three had a full recovery, two had a partial recovery, and one died.
  • [MeSH-major] Frontal Lobe / blood supply. Hodgkin Disease / diagnosis. Paraneoplastic Syndromes / diagnosis. Temporal Lobe / blood supply. Vasculitis, Central Nervous System / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10834654.001).
  • [ISSN] 0148-396X
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


16. Carr DR, Heffernan MP: Off-label uses of rituximab in dermatology. Dermatol Ther; 2007 Jul-Aug;20(4):277-87
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since its approval in 1997 by the FDA, rituximab has been approved for use in certain B-cell lymphomas and treatment-resistant rheumatoid arthritis.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antigens, CD20 / immunology. Skin Diseases / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Humans. Lymphoma, B-Cell / drug therapy. Paraneoplastic Syndromes / drug therapy. Pemphigus / drug therapy. Rituximab. Skin Neoplasms / drug therapy. Vasculitis / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17970893.001).
  • [ISSN] 1396-0296
  • [Journal-full-title] Dermatologic therapy
  • [ISO-abbreviation] Dermatol Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 113
  •  go-up   go-down


17. Bayer-Garner IB, Smoller BR: The spectrum of cutaneous disease in multiple myeloma. J Am Acad Dermatol; 2003 Apr;48(4):497-507
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Files were searched for bone-marrow diagnosis, and for type and number of transplants.
  • Skin biopsy specimen diagnoses included neoplastic lesions, (111; 73 malignant, 38 benign), graft-versus-host disease (120), drug-related lesions (46), cutaneous eruption of lymphocyte recovery (3), thrombocytopenia-related lesions (9), normolipemic plane xanthoma (1), amyloidosis (1), Sweet's syndrome (7), panniculitis (1), papulosquamous lesions (18), bullous diseases (17), vasculitis (11), infectious lesions (41), granulomatous dermatitis (6), alopecia cicatrisata (1), nonspecific lesions (77), and unrelated lesions (2).
  • CONCLUSIONS: Skin biopsy specimens from patients with MM less than 60 days from transplant most commonly show sequelae of the transplant such as graft-versus-host disease, Grover's disease (as a result of leukocytopenia and fever, waiting for engraftment), drug eruptions, chemotherapy effect, thrombocytopenic effect, cutaneous eruption of lymphocyte recovery, and Sweet's syndrome (possibly as a result of granulocyte-macrophage colony-stimulating factor).
  • Biopsy specimens taken more than 60 days from transplant most commonly show graft-versus-host disease, drug eruptions, and Sweet's syndrome but also show unrelated conditions such as neoplastic lesions, nevi, papulosquamous lesions, vasculitis, infections, and nonspecific changes.
  • [MeSH-major] Multiple Myeloma / complications. Paraneoplastic Syndromes / pathology. Skin Diseases / complications

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12664010.001).
  • [ISSN] 0190-9622
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Dingli D, Larson DR, Plevak MF, Grande JP, Kyle RA: Focal and segmental glomerulosclerosis and plasma cell proliferative disorders. Am J Kidney Dis; 2005 Aug;46(2):278-82
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The natural history of the condition varies, and although it may be responsive to therapy, FSGS is an important cause of end-stage renal disease.
  • FSGS can be caused by a variety of conditions, but it has been reported rarely in association with a plasma cell disorder.
  • RESULTS: A cohort of 13 patients with "idiopathic" FSGS and a monoclonal plasma cell disorder were identified.
  • Therapy for the underlying plasma cell disorder can lead to resolution of FSGS.
  • Thus, physicians must rule out a plasma cell proliferative disorder in patients with FSGS before concluding that the renal lesion is idiopathic.
  • Moreover, FSGS may respond favorably after the underlying plasma cell disorder is controlled.
  • [MeSH-major] Glomerulosclerosis, Focal Segmental / etiology. Paraneoplastic Syndromes / etiology. Paraproteinemias / complications
  • [MeSH-minor] Aged. Amyloidosis / etiology. Amyloidosis / pathology. Antibodies, Monoclonal / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Cohort Studies. Combined Modality Therapy. Comorbidity. Cytokines / physiology. Databases, Factual. Dexamethasone / administration & dosage. Female. Humans. Immunoglobulin Light Chains / metabolism. Kidney / metabolism. Kidney / pathology. Male. Melphalan / administration & dosage. Metabolic Clearance Rate. Middle Aged. Multiple Myeloma / complications. Multiple Myeloma / drug therapy. Multiple Myeloma / physiopathology. Multiple Myeloma / therapy. Myeloma Proteins / metabolism. Peripheral Blood Stem Cell Transplantation. Prednisone / administration & dosage. Prevalence. Proteinuria / etiology. Recurrence. Remission Induction. Retrospective Studies. Time Factors. Vasculitis / complications. Vasculitis / pathology

  • Genetic Alliance. consumer health - Focal Segmental Glomerulosclerosis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16112046.001).
  • [ISSN] 1523-6838
  • [Journal-full-title] American journal of kidney diseases : the official journal of the National Kidney Foundation
  • [ISO-abbreviation] Am. J. Kidney Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Cytokines; 0 / Immunoglobulin Light Chains; 0 / Myeloma Proteins; 7S5I7G3JQL / Dexamethasone; Q41OR9510P / Melphalan; VB0R961HZT / Prednisone
  • [Number-of-references] 28
  •  go-up   go-down


19. Conron M, Beynon HL: Ketoconazole for the treatment of refractory hypercalcemic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis; 2000 Oct;17(3):277-80
Hazardous Substances Data Bank. KETOCONAZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ketoconazole for the treatment of refractory hypercalcemic sarcoidosis.
  • Systemic corticosteroids inhibit 1,25-hydroxyvitamin D3 production, but long term therapy is often required to maintain normocalcemia.
  • Ketoconazole is an imidazole antifungal that inhibits macrophage 1 alpha-hydroxylation of 25-hydroxyvitamin D3 and has been used in paraneoplastic hypercalcemia.
  • We report a case series of four patients with relative contraindications to corticosteroids in whom treatment with ketoconazole allowed cessation or reduction in the maintenance dose of corticosteroids.
  • We conclude that ketoconazole should be considered as an alternative therapy for hypercalcemic sarcoidosis when corticosteroids are relatively contraindicated.

  • Genetic Alliance. consumer health - Sarcoidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11033844.001).
  • [ISSN] 1124-0490
  • [Journal-full-title] Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG
  • [ISO-abbreviation] Sarcoidosis Vasc Diffuse Lung Dis
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; R9400W927I / Ketoconazole
  •  go-up   go-down


20. Ehrenfeld M, Abu-Shakra M, Buskila D, Shoenfeld Y: The dual association between lymphoma and autoimmunity. Blood Cells Mol Dis; 2001 Jul-Aug;27(4):750-6
Hazardous Substances Data Bank. AZATHIOPRINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Antigens, Neoplasm / immunology. Arthritis, Rheumatoid / complications. Arthritis, Rheumatoid / drug therapy. Arthritis, Rheumatoid / epidemiology. Autoantibodies / analysis. Autoantibodies / immunology. Autoantigens / immunology. Azathioprine / adverse effects. Cell Transformation, Neoplastic / chemically induced. Cell Transformation, Neoplastic / immunology. Cohort Studies. Comorbidity. Disease Susceptibility. Genetic Predisposition to Disease. HLA Antigens / genetics. Immunosuppressive Agents / adverse effects. Lupus Erythematosus, Systemic / complications. Lupus Erythematosus, Systemic / epidemiology. Lymphoproliferative Disorders / chemically induced. Lymphoproliferative Disorders / epidemiology. Lymphoproliferative Disorders / etiology. Lymphoproliferative Disorders / immunology. Paraneoplastic Syndromes / etiology. Paraneoplastic Syndromes / immunology. Prospective Studies. Retrospective Studies. Risk. Sjogren's Syndrome / complications. Sjogren's Syndrome / drug therapy. Sjogren's Syndrome / epidemiology. Vasculitis / complications. Vasculitis / epidemiology

  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11778659.001).
  • [ISSN] 1079-9796
  • [Journal-full-title] Blood cells, molecules & diseases
  • [ISO-abbreviation] Blood Cells Mol. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Autoantibodies; 0 / Autoantigens; 0 / HLA Antigens; 0 / Immunosuppressive Agents; MRK240IY2L / Azathioprine
  • [Number-of-references] 62
  •  go-up   go-down


21. Lozsadi DA, Wieshmann U, Enevoldson TP: Neurological presentation of intravascular lymphoma: report of two cases and discussion of diagnostic challenges. Eur J Neurol; 2005 Sep;12(9):710-4
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As remission may be induced in almost half of patients with combination chemotherapy, early diagnosis of this rare disease is essential.
  • As the disease progressed, she developed nephrotic syndrome and thrombocytopenia.
  • Our cases illustrate that IVL should be considered in the differential diagnosis of cerebral and systemic vasculitis and subacute bacterial endocarditis.
  • Literature suggests IVL can also mimic Creutzfeld-Jakob disease and paraneoplastic encephalomyelitis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16128873.001).
  • [ISSN] 1351-5101
  • [Journal-full-title] European journal of neurology
  • [ISO-abbreviation] Eur. J. Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


22. Thakker MM, Perez VL, Moulin A, Cremers SL, Foster CS: Multifocal nodular episcleritis and scleritis with undiagnosed Hodgkin's lymphoma. Ophthalmology; 2003 May;110(5):1057-60
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient was found to have multifocal nodular episcleritis and scleritis that was not responsive to topical steroids or systemic nonsteroidal anti-inflammatory treatment.
  • Histopathologic analysis of an episcleral nodule revealed a necrotizing granuloma with vasculitis.
  • Systemic chemotherapy was instituted for the Hodgkin's disease; this therapy abolished the nodular scleritis.
  • CONCLUSIONS: This case raises the possibility of concurrent undiagnosed systemic vasculitis with only an ocular manifestation with Hodgkin's lymphoma, either as a coincidence or as a paraneoplastic syndrome.
  • Moreover, it emphasizes the important role of tissue biopsy in establishing diagnosis and directing treatment.
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Female. Humans. Lymph Nodes / pathology. Lymphatic Metastasis

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 by the American Academy of Ophthalmology.
  • (PMID = 12750114.001).
  • [ISSN] 0161-6420
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


23. Mocellin R, Walterfang M, Velakoulis D: Hashimoto's encephalopathy : epidemiology, pathogenesis and management. CNS Drugs; 2007;21(10):799-811
MedlinePlus Health Information. consumer health - Steroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thyroid function is usually clinically and biochemically normal.Hashimoto's encephalopathy appears to be a rare disorder, but, as it is responsive to treatment with corticosteroids, it must be considered in cases of 'investigation negative encephalopathies'.
  • Common differential diagnoses when these conditions are excluded are Creutzfeldt-Jakob disease, rapidly progressive dementias, and paraneoplastic and nonparaneoplastic limbic encephalitis.
  • Treatment with corticosteroids is almost always successful, although relapse may occur if this treatment is ceased abruptly.
  • It is likely that antithyroid antibodies are not pathogenic, but titres can be a marker of treatment response.
  • Pathological findings can suggest an inflammatory process, but features of a severe vasculitis are often absent.
  • [MeSH-major] Adrenal Cortex Hormones / therapeutic use. Brain Diseases / drug therapy. Hashimoto Disease / drug therapy
  • [MeSH-minor] Autoantibodies / blood. Autoantibodies / immunology. Humans. Prevalence. Thyroid Gland / drug effects. Thyroid Gland / immunology. Thyroid Gland / pathology

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurol Neurosurg Psychiatry. 2003 Jul;74(7):1009; author reply 1009 [12810814.001]
  • [Cites] Seizure. 2001 Sep;10(6):438-41 [11700999.001]
  • [Cites] Neurology. 2000 Feb 8;54(3):737-9 [10680814.001]
  • [Cites] Brain. 2005 Sep;128(Pt 9):2016-25 [15901648.001]
  • [Cites] Pituitary. 2006;9(1):35-45 [16703407.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2000 Jun;68(6):795 [10877624.001]
  • [Cites] Mov Disord. 2002 Sep;17(5):1091-2 [12360567.001]
  • [Cites] Lancet. 1966 Sep 3;2(7462):512-4 [4161638.001]
  • [Cites] Rheumatology (Oxford). 2002 Jun;41(6):619-30 [12048287.001]
  • [Cites] Neurology. 1999 Sep 11;53(4):858-60 [10489055.001]
  • [Cites] Endocr Rev. 2003 Oct;24(5):694-717 [14570752.001]
  • [Cites] Eur J Intern Med. 2003 Nov;14(7):434-437 [14614977.001]
  • [Cites] Acta Neurol Scand. 2005 May;111(5):338-43 [15819715.001]
  • [Cites] Postgrad Med J. 2001 Jan;77(903):56D [11123409.001]
  • [Cites] J Neurol Sci. 2004 Jan 15;217(1):7-12 [14675602.001]
  • [Cites] Joint Bone Spine. 2006 Dec;73(6):639-45 [17064944.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2005 Mar;76(3):455-6 [15716552.001]
  • [Cites] J Neurol Sci. 2005 Aug 15;235(1-2):75-6; author reply 77 [15949816.001]
  • [Cites] N Engl J Med. 1998 Dec 31;339(27):1994-2004 [9869672.001]
  • [Cites] Neuroradiology. 2006 Jun;48(6):380-6 [16586118.001]
  • [Cites] Neurology. 2003 Oct 28;61(8):1124-6 [14581677.001]
  • [Cites] Neurology. 2002 Feb 12;58(3):504-5 [11839870.001]
  • [Cites] Neurology. 2002 Nov 26;59(10 ):1633-5 [12451212.001]
  • [Cites] Intern Med. 2006;45(21):1249-52 [17139127.001]
  • [Cites] Rheumatology (Oxford). 2002 Jun;41(6):605-18 [12048286.001]
  • [Cites] Brain. 2004 Mar;127(Pt 3):701-12 [14960497.001]
  • [Cites] Arch Neurol. 2006 Feb;63(2):197-202 [16476807.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2001 Jul;71(1):33-9 [11413259.001]
  • [Cites] Aust N Z J Psychiatry. 1998 Aug;32(4):511-22 [9711365.001]
  • [Cites] FEBS Lett. 2002 Sep 25;528(1-3):197-202 [12297304.001]
  • [Cites] Eur J Paediatr Neurol. 2007 Mar;11(2):90-5 [17188007.001]
  • [Cites] J Neurol Sci. 2004 Feb 15;217(2):165-8 [14706219.001]
  • [Cites] Pediatr Neurol. 1999 May;20(5):394-8 [10371389.001]
  • [Cites] Pediatr Endocrinol Rev. 2005 Sep;3(1):20-32 [16369210.001]
  • [Cites] Eur J Paediatr Neurol. 2000;4(6):279-82 [11277369.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Feb;87(2):489-99 [11836274.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2001 Jul;71(1):81-7 [11413268.001]
  • [Cites] J Rheumatol. 2003 May;30(5):985-92 [12734893.001]
  • [Cites] Bipolar Disord. 2005 Jun;7(3):292-7 [15898968.001]
  • [Cites] Neurol India. 2004 Jun;52(2):245-7 [15269483.001]
  • [Cites] Endocr Rev. 2005 Aug;26(5):599-614 [15634713.001]
  • [Cites] J Neurol. 1996 Aug;243(8):585-93 [8865025.001]
  • [Cites] Neuropathology. 2004 Jun;24(2):149-52 [15139593.001]
  • [Cites] AJR Am J Roentgenol. 2001 Aug;177(2):455-9 [11461882.001]
  • [Cites] Neurology. 2003 Feb 25;60(4):712-4 [12601119.001]
  • [Cites] J Neurol. 2002 Aug;249(8):1063-5 [12195455.001]
  • [Cites] AJNR Am J Neuroradiol. 2004 May;25(5):807-8 [15140725.001]
  • [Cites] J Neurol Sci. 2000 May 1;176(1):65-9 [10865094.001]
  • [Cites] Pediatrics. 2003 Sep;112(3 Pt 1):686-90 [12949305.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Jul;81(7):2595-600 [8675583.001]
  • [Cites] J Neurosurg. 2007 Jan;106(1):72-5 [17236490.001]
  • [Cites] J Rheumatol. 2001 Mar;28(3):465-6 [11296942.001]
  • [Cites] Neurology. 1999 Oct 22;53(7):1579-81 [10534272.001]
  • [Cites] J Geriatr Psychiatry Neurol. 2002 Fall;15(3):175-9 [12230088.001]
  • [Cites] J Neuroimmunol. 2005 May;162(1-2):130-6 [15833368.001]
  • [Cites] Epilepsy Behav. 2006 Feb;8(1):328-30 [16343998.001]
  • [Cites] Clin Neurophysiol. 2003 Jan;114(1):32-7 [12495761.001]
  • [Cites] Parkinsonism Relat Disord. 2003 Mar;9(4):185-92 [12618052.001]
  • [Cites] Neurology. 1997 Jul;49(1):246-7 [9222197.001]
  • [Cites] J Geriatr Psychiatry Neurol. 2002 Winter;15(4):188-94 [12489914.001]
  • [Cites] Comput Med Imaging Graph. 2002 Sep-Oct;26(5):339-42 [12204239.001]
  • [Cites] Ann Rheum Dis. 2005 Feb;64(2):176-8 [15647424.001]
  • [Cites] Thyroid. 2002 May;12(5):393-8 [12097200.001]
  • [Cites] Curr Med Chem. 2003 Oct;10(19):1945-53 [12871097.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1999 Feb;66(2):172-6 [10071095.001]
  • [Cites] Neurology. 1991 Feb;41(2 ( Pt 1)):228-33 [1992366.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2001 Jan;70(1):132 [11118266.001]
  • [Cites] Ir Med J. 2000 Jun;93(4):118 [11037572.001]
  • [Cites] Arch Neurol. 2006 Feb;63(2):175-6 [16476805.001]
  • [Cites] J Neuropsychiatry Clin Neurosci. 2006 Winter;18(1):14-20 [16525066.001]
  • [Cites] Arch Neurol. 2003 Feb;60(2):164-71 [12580699.001]
  • [Cites] J Clin Neurosci. 2006 Jul;13(6):661-5 [16815706.001]
  • [Cites] Neurology. 2004 Apr 13;62(7):1177-82 [15079019.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Nov;61(11):935-46 [12430710.001]
  • [Cites] Neurology. 2003 Feb 11;60(3):523-4 [12578948.001]
  • [Cites] Thyroid. 2003 Feb;13(2):227-8 [12699601.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2005 Mar;19(1):53-66 [15826922.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 2001;109(1):35-40 [11573137.001]
  • [Cites] Semin Clin Neuropsychiatry. 2003 Jan;8(1):46-57 [12567332.001]
  • [Cites] Semin Arthritis Rheum. 2003 Jun;32(6):370-7 [12833245.001]
  • [Cites] Mov Disord. 2003 Oct;18(10 ):1175-8 [14534923.001]
  • [Cites] J Neurol. 2004 Oct;251(10):1273-4 [15503111.001]
  • [Cites] J Neurol Sci. 2005 Jan 15;228(1):3-5 [15607202.001]
  • [Cites] Mov Disord. 2003 Nov;18(11):1224-32 [14639661.001]
  • [Cites] Neurology. 1997 Aug;49(2):623-6 [9270613.001]
  • [Cites] Eur Neurol. 1999;41(2):79-84 [10023109.001]
  • [Cites] J Neurol. 2003 May;250(5):627-8 [12814119.001]
  • [Cites] Lancet Neurol. 2005 Jun;4(6):381-8 [15907743.001]
  • [Cites] AJR Am J Roentgenol. 1999 Dec;173(6):1494-6 [10584789.001]
  • [Cites] Curr Rheumatol Rep. 2006 Aug;8(4):292-8 [16839508.001]
  • [Cites] Lupus. 2003;12(12):935-42 [14714914.001]
  • (PMID = 17850170.001).
  • [ISSN] 1172-7047
  • [Journal-full-title] CNS drugs
  • [ISO-abbreviation] CNS Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Autoantibodies
  • [Number-of-references] 91
  •  go-up   go-down


24. Wilson D, McCluggage WG, Wright GD: Urticarial vasculitis: a paraneoplastic presentation of B-cell non-Hodgkin's lymphoma. Rheumatology (Oxford); 2002 Apr;41(4):476-7
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urticarial vasculitis: a paraneoplastic presentation of B-cell non-Hodgkin's lymphoma.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Paraneoplastic Syndromes / pathology. Urticaria / pathology. Vasculitis, Leukocytoclastic, Cutaneous / pathology
  • [MeSH-minor] Drug Therapy, Combination. Female. Humans. Methotrexate / therapeutic use. Middle Aged. Prednisolone / therapeutic use

  • Genetic Alliance. consumer health - Vasculitis.
  • MedlinePlus Health Information. consumer health - Hives.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11961187.001).
  • [ISSN] 1462-0324
  • [Journal-full-title] Rheumatology (Oxford, England)
  • [ISO-abbreviation] Rheumatology (Oxford)
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 9PHQ9Y1OLM / Prednisolone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


25. Marglani O, Al-Herabi A, Odell P: Marantic endocarditis as an unusual paraneoplastic syndrome of head and neck squamous cell carcinoma. J Otolaryngol Head Neck Surg; 2009 Apr;38(2):E76-7
MedlinePlus Health Information. consumer health - Endocarditis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Marantic endocarditis as an unusual paraneoplastic syndrome of head and neck squamous cell carcinoma.
  • [MeSH-major] Anticoagulants / therapeutic use. Carcinoma, Squamous Cell. Endocarditis / complications. Paraneoplastic Syndromes / pathology. Tonsillar Neoplasms
  • [MeSH-minor] Aged. Coronary Thrombosis / complications. Coronary Thrombosis / diagnosis. Coronary Thrombosis / drug therapy. Fingers. Humans. Male. Vasculitis / complications. Vasculitis / drug therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Endocarditis.
  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19442361.001).
  • [ISSN] 1916-0216
  • [Journal-full-title] Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale
  • [ISO-abbreviation] J Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Anticoagulants
  •  go-up   go-down


26. Borde JP, Offensperger WB: [64-year-old patient with efflorescences on the upper and lower legs]. Dtsch Med Wochenschr; 2010 Sep;135(36):1737-8
Hazardous Substances Data Bank. ACYCLOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] 64-jähriger Patient mit Effloreszenzen an Ober- und Unterschenkeln.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Bromodeoxyuridine / analogs & derivatives. Herpes Zoster / diagnosis. Vasculitis, Leukocytoclastic, Cutaneous / diagnosis
  • [MeSH-minor] Acyclovir / therapeutic use. Antiviral Agents / adverse effects. Antiviral Agents / therapeutic use. Diagnosis, Differential. Esophageal Neoplasms / secondary. Exanthema / diagnosis. Exanthema / etiology. Humans. Leg. Lymphoma, Mantle-Cell / drug therapy. Male. Middle Aged. Paraneoplastic Syndromes / diagnosis

  • MedlinePlus Health Information. consumer health - Shingles.
  • Hazardous Substances Data Bank. BROMODEOXYURIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20812158.001).
  • [ISSN] 1439-4413
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antiviral Agents; 2M3055079H / brivudine; G34N38R2N1 / Bromodeoxyuridine; X4HES1O11F / Acyclovir
  •  go-up   go-down


27. Arias-Santiago S, Aneiros-Fernández J, Girón-Prieto MS, Fernández-Pugnaire MA, Naranjo-Sintes R: Palpable purpura. Cleve Clin J Med; 2010 Mar;77(3):205-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / diagnosis. Adrenal Cortex Hormones / therapeutic use. Breast Neoplasms / complications. Breast Neoplasms / diagnosis. Diagnosis, Differential. Female. Humans. Middle Aged. Paraneoplastic Syndromes / diagnosis. Paraneoplastic Syndromes / drug therapy. Vasculitis, Leukocytoclastic, Cutaneous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20200171.001).
  • [ISSN] 1939-2869
  • [Journal-full-title] Cleveland Clinic journal of medicine
  • [ISO-abbreviation] Cleve Clin J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  •  go-up   go-down






Advertisement